Feb 23 (Reuters) - Gossamer Bio said on Monday its experimental drug for patients with a type of lung condition missed the ...
A European study finds hospitalisations and insufficient growth reduce health-related quality of life in childhood ...
Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.
Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.
Rare lung diseases affect people nationwide, yet many patients go undiagnosed or misdiagnosed for years. One rare lung disease that illustrates the challenges of timely diagnosis is autoimmune pulmona ...
Gossamer Bio will be reporting the outcome of a late-stage study in pulmonary arterial hypertension. Here's what to know.
November is National Chronic Obstructive Pulmonary Disease Awareness Month. It’s time to raise awareness about lung disease within our communities. By understanding the causes, reducing our risk ...
United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...
A Los Angeles man was awarded $25 million after developing a rare chronic lung disease known as “popcorn lung” from an ...
As more research finds evidence of QOL benefits, pulmonologists ponder bringing new singing programs to their patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results